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Objective. Bisphosphonates have slowed the pro-
gression of osteoarthritis (OA) in animal models and
have decreased pain in states of high bone turnover. The
Knee OA Structural Arthritis (KOSTAR) study, which
is the largest study to date investigating a potential
structure-modifying OA drug, tested the efficacy of
risedronate in providing symptom relief and slowing
disease progression in patients with knee OA.
Methods. The study group comprised 2,483 pa-
tients with medial compartment knee OA and 2–4 mm
of joint space width (JSW), as determined using fluoro-
scopically positioned, semiflexed-view radiography. Pa-
tients were enrolled in 2 parallel 2-year studies in North
America and the European Union. These studies evalu-
ated the efficacy of risedronate at dosages of 5 mg/day,
15 mg/day, 35 mg/week (in Europe), and 50 mg/week (in
North America) compared with placebo in reducing
signs and symptoms, as measured by the Western
Ontario and McMaster Universities Osteoarthritis
(WOMAC) index and patient global assessment (PGA)
scores, and in slowing radiographic progression.
Results. A reduction of 20% in signs and symp-
toms, as measured by WOMAC subscales and PGA
scores, was observed in all groups, with no treatment
effect of risedronate demonstrated. Risedronate did not
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Cochin, Paris, France; 6Silvano Adami, MD: University of Verona,
Verona, Italy; 7Daniel J. Clauw, MD: University of Michigan, Ann
Arbor; 8Timothy D. Spector, MD, MSc, FRCP: St. Thomas Hospital,
London, UK; 9Jean-Pierre Pelletier, MD, Jean-Pierre Raynauld, MD,
FRCPC: Centre Hospitalier de l’Université de Montréal, Hôpital Notre-
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significantly reduce radiographic progression as mea-
sured by decreased JSW or using a dichotomous defini-
tion of progression (joint space loss of >0.6 mm).
Thirteen percent of patients receiving placebo demon-
strated significant disease progression over 2 years. A
dose-dependent reduction in the level of C-terminal
crosslinking telopeptide of type II collagen, a cartilage
degradation marker associated with progressive OA,
was seen in patients who received risedronate. No
increase in the number of adverse events was demon-
strated for risedronate compared with placebo.
Conclusion. Although risedronate (compared
with placebo) did not improve signs or symptoms of OA,
nor did it alter progression of OA, a reduction in the
level of a marker of cartilage degradation was observed.
A sustained clinically relevant improvement in signs
and symptoms was observed in all treatment and pla-
cebo groups.
Osteoarthritis (OA) is the most prevalent form of
arthritis, affecting more than 10% of the population and
an estimated 21 million adults in the US (1). The disease
is associated with significant pain and disability and is a
major factor necessitating hip or knee replacement. OA
is characterized by focal cartilage loss, subchondral bony
changes, osteophyte formation, and (in some cases)
synovitis with involvement of periarticular structures.
Most pharmacologic therapy for OA is directed toward
symptom control, using analgesics, nonsteroidal antiin-
flammatory drugs (NSAIDs), and cyclooxygenase 2
(COX-2) inhibitors. Weight loss, physical therapy, and
activity are also important components of treatment. To
date, there has been limited evidence for therapies that
slow the disease process. Although glucosamine has
been advocated as a possible structure-modifying OA
drug (SMOAD) (2), data are inconsistent, and questions
remain as to its absorption and putative action (3,4).
Recent data have suggested a possible benefit of doxy-
cycline in slowing radiographic progression (but not
altering symptoms) in obese women with knee OA (5).
Treatment with diacerein slowed radiographic pro-
gression in patients with hip OA over 3 years but had
no effect on signs and symptoms (6,7). Evaluating
drugs as potential SMOADs presents significant chal-
lenges for developing appropriate study designs and
outcomes.
Failure of the OA joint represents cartilage de-
gradation but may also reflect changes in subchondral
bone, with decreased numbers and thinning of tibial
cancellous trabeculae and localized subchondral osteo-
porosis in knee OA (8–10), confirming earlier observa-
tions of periarticular osteoporosis in some patients (11).
Subchondral bone lesions, which are seen by magnetic
resonance imaging (MRI) in many patients with OA,
may represent histologic microfractures (12–14). In the
Duncan-Hartley guinea pig model of spontaneous OA,
subchondral bony changes are a characteristic of the
disease process (15), and risedronate inhibited histologic
disease progression, with a 30–40% reduction in carti-
lage damage (16–18). Bisphosphonates have also been
effective in slowing disease progression in other animal
models of OA (19,20).
Agents that suppress bone turnover, including
bisphosphonates, have been associated with fewer sub-
chondral bony lesions (as visualized by MRI) in patients
with OA (21); such lesions are independently correlated
with levels of pain and disease progression (22). Levels
of bone turnover markers are higher in patients with
progressive OA and are similar to those in patients with
postmenopausal osteoporosis (23). Data from trials of
patients with Paget’s disease indicated that short treat-
ment courses of higher-dosage risedronate (30 mg/day)
improved bone lesions, reduced biochemical indices of
disease activity (24), and reduced bone pain (25–27). In
a 1-year study, 285 patients with knee OA received
risedronate at a dosage of 5 mg/day, risedronate at a
dosage of 15 mg/day, or placebo (28). A consistent trend
for pain reduction with the highest dosage of risedronate
was observed at 6 months, and a consistent trend for
statistically significantly different responses in patient
global assessment of disease (PGA) scores was observed
at 1 year. Although these differences suggested a possi-
ble benefit in retarding radiographic progression, with
1% of patients in the group receiving risedronate at a
dosage of 15 mg/day showing disease progression
(0.75-mm joint space loss) over 1 year compared with
8% of patients in the placebo group, the differences
were not statistically significant. A dose-dependent re-
duction in the level of urinary C-terminal crosslinking
telopeptide of type II collagen (CTX-II) was also ob-
served in that study. Thus, there is rationale for suggest-
ing that a bisphosphonate, potentially acting to inhibit
bone turnover, may have a role in the treatment of OA.
Risedronate, a pyridinyl bisphosphonate that de-
creases bone resorption and turnover, is efficacious for
postmenopausal and corticosteroid-induced osteo-
porosis and, in higher doses, for Paget’s disease of bone
(26,27,29,30). We explored the efficacy of risedronate, in
a range of doses, in knee OA.
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PATIENTS AND METHODS
Study design. Two parallel phase III studies were
conducted in North American and European Union sites,
respectively. These were 2-year, multicenter, randomized,
double-blind, placebo-controlled studies of oral risedronate at
dosages of 5 mg/day, 15 mg/day, and 35 mg/week (European
sites) or 5 mg/day, 15 mg/day, and 50 mg/week (North Amer-
ican sites) in patients with medial compartment knee OA. The
studies were conducted in 42 centers in North America (US
and Canada) and in 44 European centers (11 countries). All
patients provided written informed consent before entering the
study, which was conducted in accordance with International
Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use Guidelines
for Good Clinical Practice and was administered by local and
central institutional review boards.
Male and female patients, ages 40–80 years (inclusive),
were recruited. Patients who underwent screening had signal
knee pain due to OA on most days during at least 1 month in
a 3-month period prior to screening, plus at least 1 of the
following: age 50 years, morning knee stiffness lasting 30
minutes, or knee crepitus according to the American College
of Rheumatology (formerly, the American Rheumatism Asso-
ciation) criteria for knee OA (31). All patients then underwent
radiography of the knee, to confirm the presence of OA. A
specified minimum or maximum level of background pain was
not required for inclusion in the study.
Major exclusions were the following: known inflamma-
tory arthritis, body mass index (BMI) 40 kg/m2, cancer within
10 years, tetracycline use within 6 months, intraarticular injec-
tion of corticosteroids or hyaluronan preparations within 3
months, calcitonin or fluoride use within 6 months, and prior
use of bisphosphonates within 12 months or for 60 days ever.
To determine whether patients had a qualifying knee
radiograph, standardized radiography with fluoroscopically
positioned semiflexed anteroposterior (AP) views was used.
The SD for this technique was 0.2 mm for radiographs
obtained 2 days apart, based on repeat measurements (32). At
least 1 osteophyte and minimal joint space width (JSW) of 2–4
mm, inclusive, in the medial tibiofemoral compartment, and a
medial compartment that was narrower than the lateral were
required. If both knees qualified, the signal knee was defined
as the knee with the smaller JSW. Radiographic assessments
were conducted at baseline, 1 year, and 2 years. Patients who
withdrew were asked to return for the 24-month assessment,
which included radiography.
Treatment assignment. Equal proportions of North
American patients were assigned to receive either placebo,
risedronate 5 mg/day, risedronate 15 mg/day, or risedronate 50
mg/week. Equal proportions of European patients were as-
signed to receive either placebo, risedronate 5 mg/day, risedr-
onate 15 mg/day, or risedronate 35 mg/week. At each center,
patients were randomized to treatment groups and stratified
according to current use of estrogens/selective estrogen recep-
tor modulators (SERMs).
Patients were instructed to take the study drug with
sufficient plain water, once daily while in an upright position,
with an empty stomach in the morning at least 30 minutes
before eating or drinking anything, or, at other times during
the day, at least 2 hours before or after eating or drinking and
not less than 30 minutes before bedtime.
The dosages of risedronate used in these studies were
based on the dosage used for postmenopausal osteoporosis (5
mg/day) and a daily dose of 15 mg, which was believed to
clearly separate from the 5 mg/day dosage with regard to
serum concentrations. The weekly dosing groups (35 mg/week
in Europeans and 50 mg/week in North Americans) were
included to provide the opportunity to evaluate the efficacy of
a more convenient weekly dosing regimen, with the 50 mg/
week dosage chosen to provide information regarding an
intermediate total weekly dose.
Background analgesics and stepped reduction. Non-
narcotic analgesics, NSAIDs, or COX-2 inhibitors were per-
mitted and monitored, with changes according to physician
preference and clinical course. All patients underwent a
stepped analgesic reduction and washout period before study
visits, including the baseline visit. Each patient was provided
with acetaminophen (North America)/paracetamol (Europe)
(500 mg) and diclofenac (50 mg), to be used as needed as the
only pain medications from day 5 to day 3 preceding the
baseline, 6-, 12-, 18-, and 24-month visits. All pain medications
were discontinued on day 2 and day 1 prior to these visits
and on the visit day. WOMAC and PGA questions referred to
the preceding 48 hours.
Treatment outcomes. The coprimary efficacy objec-
tives were to assess the effect of risedronate on structure and
symptoms in patients with mild to moderate knee OA relative
to placebo. OA symptoms were measured by the Western
Ontario and McMaster Universities Osteoarthritis (WOMAC)
index (33) and by PGA scores. WOMAC measurements were
collected on a 100-mm visual analog scale. Questionnaires and
assessment instruments in the local languages were provided to
the investigative sites. Standardized training was provided at
investigator meetings in North America and Europe and was
monitored throughout the study.
The average values for each domain were calculated
and reported at each time point. The total WOMAC score was
calculated as the sum of individual measurements divided by
the total number of questions. Structure was assessed by
measuring the progression of joint space narrowing (JSN) in
the medial tibiofemoral compartment in the pooled North
American and European studies after 2 years.
Radiographic assessment. The JSW of the target knee
was evaluated at baseline and after 1 and 2 years of followup,
at the narrowest point in the medial tibiofemoral compartment
(32,34,35). This protocol standardized radiographs with a
semiflexed view of the knee, aided by fluoroscopy, and by
attaching a metal sphere to the fibula head to correct magni-
fication effects. Minimum medial compartment JSW was mea-
sured with a semiautomated computerized method.
To ensure proper quality, exposure, positioning of the
knee joint, and reproducibility of the JSW measurements,
radiographs were obtained at 13 regional radiographic facili-
ties (RRFs) in Europe and 12 RRFs in the US, by specially
trained personnel (32); quality, exposure, positioning, and
acceptability were checked on an ongoing basis. A standing AP
fluoroscopically assisted semiflexed view of the signal knee was
obtained according to the procedure described by Buckland-
Wright and was shown to be accurate and reproducible (34,35).
Each knee was flexed until the tibial plateau was horizontal
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relative to the floor, parallel to the central x-ray beam and
perpendicular to the radiograph film. The center of the joint,
defined by the joint space, was aligned with the center of the
x-ray beam with the aid of the tube’s positioning light.
The precise knee position was obtained visually with
the aid of fluoroscopy. With the heel fixed, the foot was
internally or externally rotated until the tibial spines appeared
centrally placed relative to the femoral notch; then, the knee
was flexed to achieve superimposition (1 mm) of the anterior
and posterior margins of the medial tibial plateau. All radio-
graphs were sent to the Radiographic Quality Control Centre
(RQCC) in Amsterdam, The Netherlands (European patients)
or to the RQCC in Ann Arbor, Michigan (North American
patients), where radiographs had to pass strict quality control
measures, and then on to the Central Analysis Facility at
King’s College in London, where the films were digitized, and
semiautomated computerized measurements of minimal me-
dial JSW were performed. This is a highly reproducible image
analysis technique. For this technique, the test–retest SD for
the difference between radiographs obtained 2 days apart was
0.2 mm. The coefficient of variation for the reproducibility of
the software to measure medial compartment JSW had been
determined previously as 1% for test–retest radiographs of the
knee in the semiflexed position (34).
Osteophytes were assessed manually on temporally
ordered films by 2 radiologists and scored (if present) on the
medial tibial edge, the lateral tibial edge, or the tibial spine.
Baseline and exit films were graded according to the Osteoar-
thritis Research Society International osteophyte grading con-
ventions on a 0–3 scale, using a reference manual (36). The
percent change in osteophyte size relative to baseline was also
graded, as follows: 0  no definite growth, 1  50% growth,
2  growth 50% and 100%, 3  100% growth. In a small
validation substudy of the percent change in osteophyte size
parameter, the percent of exact matches of osteophyte scores
ranged from 87–97% for intrareader agreement and 74–95%
for interreader agreement.
Safety ssessments. Safety data, including physical ex-
amination, vital signs, laboratory evaluations, concomitant
medications, and adverse events, were collected from all
patients every 3 months. Adverse events were coded according
to COSTART (Coding Symbols for a Thesaurus of Adverse
Reaction Terms) definitions, with severity and attributability
recorded.
Assessment of biochemical markers. Early-morning,
fasting, second-void urine samples were collected at baseline
and at the month 6, month 12, and month 24 (exit) visits, to
measure bone and cartilage turnover. Samples were frozen and
analyzed in bulk. Bone resorption was assessed by determining
urine levels of N-terminal crosslinking telopeptide of type I
collagen (NTX-I) (Osteomark; OrthoClinical Diagnostics,
Rochester, NY), and cartilage degradation was assessed with
urine levels of CTX-II (CartiLaps; Nordic Bioscience, Herlev,
Denmark). The detection limits of the assays were as follows:
for NTX-I, 4 nmoles of BCE/liter; for CTX-II, 0.25 g/liter.
The urinary CTX-II assay is based on a mouse monoclonal
antibody raised against the EKGPDP sequence of human type
II collagen C-telopeptide, a sequence observed exclusively in
type II collagen and not in the other collagens, including type
I, or other structural proteins. The antibody has no significant
cross-reactivity with type I collagen C-telopeptide (37). Inter-
assay variability and intraassay variability were lower than 10%
for both assays. Levels of urinary creatinine were measured for
marker normalization.
Sample size and data analysis plans. Each study was
initially designed to assure 90% power to detect a 40%
protective effect of risedronate versus placebo in reducing
JSN, assuming a 0.2-mm/year rate of JSN in the placebo
population, a SD of 0.45 mm, a 2-year dropout rate of 30%,
and a Type I error rate of 5% with Dunnett’s adjustment for
multiple-dose 2-sided comparisons with placebo, with a sample
size requirement of 302 patients per treatment group. The
study was sized for 90% power to detect a mean 0.16-mm JSN
difference between a placebo-treated and a risedronate-
treated group.
Prior to unblinding, it was determined that the mean
rate of radiographic progression among patients receiving
placebo was expected to be 0.085 mm per year, based on the
results of a smaller study using the same radiographic tech-
niques (28), rather than a rate of 0.20 mm per year, as
originally expected. As a result, the protocols were modified to
focus on a pooled JSW analysis from the combined North
American and European studies as the primary structure end
point to provide 90% power for a 50% relative risk reduction,
with a placebo-associated progression rate of 14%. The statis-
tical analysis plan specified that the primary JSW analysis was
to compare the mean JSN that occurred with placebo, pro-
vided analysis of variance (ANOVA) assumptions were met. If
ANOVA assumptions were not met, the primary structure was
to be the proportion of patients in whom disease progressed
(defined as JSW loss of 0.6 mm across treatment groups),
representing 3 times the SD of the measurement (32), which
was the case for the final analysis.
The first planned primary analysis was a comparison of
the month 24 mean change from baseline in the total WOMAC
score between patients receiving the highest dosage of risedr-
onate (15 mg/day) and patients receiving placebo, within each
study. If the total WOMAC score at month 24 was statistically
significant for the group receiving risedronate at a dosage of 15
mg/day versus the placebo group, then the pooled study JSW
and within-study PGA analyses would simultaneously be con-
ducted to compare the group receiving 15 mg/day of risedr-
onate with the placebo group, using a step-down approach.
Sign and symptom end points were evaluated by study (North
America or Europe); however, the analyses of structure exam-
ined patients in the different dose groups, pooled for the
studies.
The primary analysis of mean JSW was adjusted at
each time point by using the study (North America/European
Union), baseline use of estrogen/SERMs, sex, age, BMI, and
baseline JSW as covariates. The JSW progressor analysis used
the Cochran-Mantel-Haenszel test, with the North American
study and the European study as strata. Symptom analyses at
each time point were adjusted by using the appropriate base-
line total WOMAC score or PGA value, pooled centers,
baseline use of estrogen/SERMs, sex, age, BMI, and baseline
JSW as covariates. Mean changes from baseline in measures of
signs and symptoms were evaluated using repeated-measures
analysis adjusted for pooled centers, baseline PGA score,
baseline use of estrogen/SERMs, sex, age, BMI, and baseline
JSW. The ANOVA model was used for primary symptom
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Figure 1. Flow chart of the study. Patients who continued to receive study medica-
tion through month 24 are indicated as completers. NA  North America; EU 
European Union.












(n  314) P
Total
(n  1,232)
Age, years 60.2  0.51 60.6  0.51 60.4  0.51 60.7  0.49 0.9125 60.5  0.25
Female sex, no. (%) 178 (57) 189 (62) 196 (65) 194 (62) 0.2992 757 (61)
Race, no. (%)
Asian 6 (2) 3 (1) 4 (1) 7 (2) 20 (2)
Black 27 (9) 28 (9) 33 (11) 21 (7) 109 (9)
Hispanic 11 (4) 10 (3) 11 (4) 11 (4) 43 (3)
Other 1 (1) 7 (2) 6 (2) 5 (2) 19 (2)
White 265 (85) 258 (84) 248 (82) 270 (86) 0.6261 1,041 (84)
Height, cm 169.0  0.59 168.5  0.54 168.4  0.58 167.7  0.56 0.4677 168.4  0.28
Weight, kg 87.0  0.96 86.0  0.90 85.0  0.96 86.6  0.93 0.4708 86.2  0.47
Body mass index, kg/m2 30.4  0.28 30.2  0.27 29.9  0.27 30.7  0.27 0.2018 30.3  0.14
Postmenopausal, no. (%)† 130 (73) 148 (78) 141 (72) 150 (77) 0.4485 569 (75)
Estrogen/SERM use, no. (%)† 87 (49) 83 (44) 75 (38) 90 (46) 0.1903 335 (44)
WOMAC total score 39.7  1.29 41.0  1.27 39.6  1.29 40.6  1.31 0.8263 40.2  0.65
WOMAC pain score 36.4  1.24 37.8  1.23 37.1  1.27 37.6  1.32 0.8546 37.2  0.63
WOMAC function score 39.8  1.36 41.3  1.34 39.6  1.36 40.9  1.36 0.7733 40.4  0.67
WOMAC stiffness score 45.9  1.45 46.9  1.48 45.4  1.52 45.9  1.52 0.9198 46.0  0.75
Patient global assessment score 52.6  1.38 52.8  1.40 51.4  1.39 54.2  1.44 0.5627 52.8  0.70
Joint space width, mm 2.947  0.0335 2.970  0.0346 2.979  0.0341 2.997  0.0335 0.7626 2.973  0.0170
NSAID use, no. (%) 228 (74) 235 (77) 208 (69) 216 (69) 0.0742 887 (72)
Celecoxib use, no. (%) 53 (17) 48 (16) 54 (18) 52 (17) 0.9064 207 (17)
Rofecoxib use, no. (%) 42 (14) 53 (17) 33 (11) 40 (13) 0.1313 168 (14)
Acetaminophen use, no. (%) 138 (45) 140 (46) 145 (48) 136 (43) 0.6830 559 (45)
Glucosamine/chondroitin use, no. (%) 92 (30) 77 (25) 76 (25) 87 (28) 0.5227 332 (27)
NTX-I/Cr, nmole BCE/nmole Cr 37.48  1.964 36.27  1.001 38.80  1.072 37.62  1.009 0.6182 37.54  0.662
CTX-II/Cr, ng/nmole Cr 296.47  17.087 273.48  10.682 297.16  14.872 273.02  9.637 0.3765 284.93  6.690
* Except where indicated otherwise, values are the mean  SEM. P values indicate differences across treatment groups. The chi-square test was used
to compare categorical variables, and analysis of variance was used to compare continuous variables. SERM  selective estrogen receptor
modulator; WOMAC  Western Ontario and McMaster Universities Osteoarthritis index; NSAID  nonsteroidal antiinflammatory drug; NTX-I 
N-terminal crosslinking telopeptide of type I collagen; Cr  creatinine; CTX-II  urinary C-terminal crosslinking telopeptide of type II collagen.
† Female patients only.
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analyses. Unless noted otherwise, all statistical analyses were
2-sided, with a Type I error rate of 0.05.
The primary analyses were modified intent-to-treat
(ITT) analyses conducted using data from all randomized
patients who received at least 1 dose of study drug. In these
ITT analyses, data for some patients may have been missing,
due to missed visits, withdrawal, or other reasons. Missing data
were not imputed for the primary efficacy end points. A
per-protocol analysis for each efficacy end point was con-
ducted for patients who met all protocol inclusion/exclusion
criteria, who were compliant (taking at least 75% of the study
drug), and who had no other major deviations.
RESULTS
A total of 9,236 patients at 42 sites in North
America (US and Canada) and at 44 centers in Europe
were screened for participation in the KOSTAR study.
The most common factors involved in screening failure
were radiographic criteria, including lack of qualifying
osteophytes and JSW 4 mm or 2 mm. A total of 2,497
patients were randomized, and 2,483 were enrolled,
constituting the ITT population, with 1,232 patients in
the North American cohort and 1,251 patients in the
European cohort (Figure 1). The overall screening-to-
randomization ratio was 4:1. Overall patient retention
was very high, with 86.7% of patients completing the
final visit at 2 years, and 76.4% completing the study
without dropping out. The percentage of withdrawals in
North America (27.7%) was greater than that in Europe
(19.7%), largely because of loss to followup. The num-
bers of patients who withdrew due to adverse events
were similar across groups. No differences in the num-
ber of withdrawals were noted in either study (North
America or Europe), across treatment groups or in
combined studies.
Several differences in the clinical characteristics
of randomized patients in the North American and
European studies were noted (Tables 1 and 2). The
North American study population included more men,
and the average age of North American patients was

















Age, years 63.6  0.48 63.7  0.45 62.9  0.47 64.1  0.48 0.2901 63.6  0.23 0.0001
Female sex, no. (%) 259 (83) 254 (79) 235 (77) 243 (78) 0.2395 991 (79) 0.0001
Race, no. (%)
Asian 3 (1) 1 (1) 1 (1) 1 (1) 6 (1)
Black 1 (1) 3 (1) 2 (1) 0 (0) 6 (1)
Hispanic 0 (0) 0 (0) 0 (0) 1 (1) 1 (1)
Other 10 (3) 10 (3) 9 (3) 14 (5) 43 (3)
White 298 (96) 308 (96) 295 (96) 294 (95) 0.6407 1,195 (96) 0.0001
Height, cm 164.4  0.45 164.6  0.46 164.6  0.49 164.6  0.48 0.9799 164.5  0.23 0.0001
Weight, kg 79.8  0.72 79.3  0.66 79.6  0.69 79.1  0.72 0.9230 79.4  0.35 0.0001
Body mass index, kg/m2 29.5  0.24 29.3  0.24 29.4  0.23 29.2  0.24 0.8494 29.4  0.12 0.0001
Postmenopausal, no. (%)§ 244 (94) 240 (94) 213 (91) 222 (91) 0.4773 919 (93) 0.0001
Estrogen/SERM use, no. (%)§ 29 (11) 31 (12) 27 (11) 35 (14) 0.6979 122 (12) 0.0001
WOMAC total score 47.0  1.16 44.5  1.16 47.1  1.17 44.6  1.21 0.2156 45.8  0.59 0.0001
WOMAC pain score 43.7  1.20 40.8  1.18 44.3  1.19 41.0  1.23 0.0766 42.4  0.60 0.0001
WOMAC function score 48.0  1.23 45.5  1.23 47.9  1.24 45.7  1.27 0.3108 46.8  0.62 0.0001
WOMAC stiffness score 47.4  1.51 45.8  1.40 47.1  1.44 44.2  1.53 0.4089 46.1  0.74 0.9444
Patient global assessment score 56.9  1.27 55.0  1.29 56.2  1.34 57.1  1.30 0.6510 56.3  0.65 0.0002
Joint space width, mm 2.976  0.0345 2.991  0.0346 2.955  0.0309 2.963  0.0337 0.8798 2.971  0.0167 0.9405
NSAID use, no. (%) 175 (56) 193 (60) 180 (59) 170 (55) 0.5541 718 (57) 0.0001
Celecoxib use, no. (%) 5 (2) 4 (1) 3 (1) 5 (2) 0.8840 17 (8) 0.0001
Rofecoxib use, no. (%) 6 (2) 2 (1) 6 (2) 12 (4) 0.0399 26 (2) 0.0001
Acetaminophen use, no. (%) 79 (25) 97 (30) 83 (27) 82 (26) 0.5654 341 (27) 0.0001
Glucosamine/chondroitin use,
no. (%)
25 (8) 26 (8) 24 (8) 25 (8) 0.9994 100 (8) 0.0001
NTX-I/Cr, nmole BCE/nmole Cr 49.43  1.364 46.79  1.307 49.91  2.097 46.20  1.241 0.2238 48.07  0.768 0.0001
CTX-II/Cr, ng/nmole Cr 376.72  13.724 367.17  13.664 360.70  12.059 361.71  16.798 0.8498 366.58  7.080 0.0001
* Except where indicated otherwise, values are the mean  SEM. The chi-square test was used to compare categorical variables, and analysis of
variance was used to compare continuous variables. NA  North America (see Table 1 for other definitions).
† Differences across treatment groups.
‡ By Fisher’s exact test for categorical variables and by analysis of variance for continuous variables.
§ Female patients only.
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younger (60.5 years versus 63.6 years in the European
study). Although more European women were post-
menopausal, more women in the North American group
took estrogen or SERMs. Patients in North America
were heavier, with a higher mean BMI (30.3 kg/m2
versus 29.4 kg/m2). The baseline total WOMAC scores,
scores for all WOMAC domains, and PGA scores were
higher in Europeans, although WOMAC scores for
stiffness were not significantly different (P  0.944).
More patients in North America were taking NSAIDS
and coxibs as analgesics. The baseline characteristics
were, however, comparable across the different treat-
ment groups within each study. The mean JSWs at
baseline in the North American and European studies
were not significantly different (P  0.9405), reflecting
standardized radiographic methods and the require-
ments for study entry.
Signs and symptoms. In both the European and
North American studies, no significant differences be-
tween treatment groups were noted in the mean change
from baseline in total WOMAC score, scores for
WOMAC components, or PGA scores (Table 3). In the
placebo-treated group, a reduction of 20% from base-
line was seen in total WOMAC scores as well as in each
subcomponent. No statistically significant differences or
trends were noted for any dose of risedronate. Similarly,
the reduction in PGA scores was of a similar magnitude
across all 5 treatment groups. Although the baseline and
final WOMAC scores, subscale scores, and PGA scores
were higher in the European group than in the North
American group, the reductions from baseline were
similar. Reductions were seen at the first time point (6
months) and were maintained throughout 2 years in all
groups (Figure 2). There was a reduction in the average
number of days and number of pills of analgesic medi-
Table 3. Changes in WOMAC and PGA scores from baseline to month 24 among patients in the North
American and European cohorts*
Placebo
Risedronate
5 mg/day 35 mg/week 50 mg/week 15 mg/day
North America
WOMAC total 9.5  1.31 7.9  1.34 – 10.8  1.33 8.2  1.38
WOMAC pain 8.4  1.34 8.2  1.39 – 9.9  1.38 7.9  1.42
WOMAC function 9.3  1.33 7.7  1.37 – 10.7  1.36 7.8  1.41
WOMAC stiffness 11.9  1.59 9.9  1.65 – 13.6  1.63 12.0  1.69
PGA 8.7  1.71 8.5  1.77 – 10.8  1.75 7.6  1.82
European Union
WOMAC total 10.0  1.63 11.2  1.58 11.6  1.60 – 11.7  1.62
WOMAC pain 10.1  1.71 11.4  1.66 12.1  1.67 – 12.3  1.70
WOMAC function 9.9  1.68 11.0  1.63 11.6  1.65 – 11.5  1.66
WOMAC stiffness 10.5  1.93 13.9  1.86 12.3  1.88 – 12.8  1.91
PGA 15.6  2.13 15.2  2.06 17.0  2.08 – 17.2  2.12
* Values are the adjusted mean  SEM. The symptom analyses at each time point were adjusted using the
appropriate baseline Western Ontario and McMaster Universities Osteoarthritis index (WOMAC) total
score or patient global assessment (PGA) score, pooled centers, baseline use of estrogens or selective
estrogen receptor modulators, sex, age, body mass index, and baseline joint space width as covariates.
Figure 2. Adjusted mean  SEM changes from baseline in total
Western Ontario and McMaster Universities Osteoarthritis
(WOMAC) and WOMAC pain subscale scores over 24 months. The
symptom analyses at each time point were adjusted using the appro-
priate baseline WOMAC score, pooled centers, baseline use of
estrogen or selective estrogen receptor modulators, sex, age, body
mass index, and baseline joint space width as covariates. Ris 
risedronate.
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cation taken per week in the placebo group and all
treatment groups in North America and Europe, with no
differences noted with any risedronate dose compared
with placebo (data not shown).
Radiographic changes. Because in the combined
symptomatic analysis of 15 mg/day of risedronate versus
placebo, ANOVA assumptions were not met using the
prespecified definitions, the primary analysis for struc-
ture modification was performed using JSW progression
as the end point. The proportion of patients experienc-
ing radiographic progression, defined as 0.6 mm of
JSN over 24 months, was 13% overall, with no statisti-
cally significant differences noted in any treatment
group or in the North American versus European co-
horts (Table 4). Although the proportion of JSW pro-
gressors was small at 2 years, it was similar to that
extrapolated based on progression among patients re-
ceiving placebo in the pilot study (31) on which this
analysis was modeled.
Most patients had no radiographic worsening,
defined as JSN of 0.6 mm. An approximate normal
distribution within 3 SD of the measurement error was
observed (Figure 3). Although a few patients could be
classified as having joint space “improvement,” this is
most likely attributable to expected measurement error
in joint space over 2 years. Far more patients were
represented within the progression “tail,” with many
progressors demonstrating marked loss of joint space of
1 mm and sometimes 2 mm.
The observed mean  SD reductions in JSW in
the placebo groups over 24 months were 0.088  0.040
mm in the European cohort and 0.130  0.033 mm in
the North American cohort. No statistically significant
differences were noted for any dose of risedronate
compared with placebo, for either study or for the
combined data (data not shown). Although in this study,
changes in grading according to the Kellgren/Lawrence
scale (38) were not specifically evaluated, there was no
difference between treatment groups in medial, lateral,
or tibial spine osteophyte changes at 2 years. In the
different treatment groups, 26–37% of patients had
worsening of medial spine osteophytes, 10–22% had
worsening of lateral spine osteophytes, and 3–19% had
worsening of tibial spine osteophytes, with no group
demonstrating trends or statistically significant differ-
ences compared with placebo (data not shown).











No. of radiographs 269 268 268 260 1,065
No. (%) progressors 37 (14) 43 (16) 38 (14) 36 (14) 154 (14)
European Union
No. of radiographs 280 305 280 283 1,148
No. (%) progressors 35 (13) 35 (11) 31 (11) 39 (14) 140 (12)
Combined total
No. of radiographs 549 573 280 268 543 2,213
No. (%) progressors 72 (13) 78 (14) 31 (11) 38 (14) 75 (14) 294 (13)
* The narrowest medial compartment joint space width (JSW) was measured using standardized fluoroscopically positioned
semiflexed-view knee radiographs obtained at baseline, 12 months, and 24 months, in the North American, European, or
combined studies. A patient was defined as a progressor using a dichotomous definition of a 0.6 mm decrease in JSW from
baseline at any postbaseline measurement. JSN  joint space narrowing.
Figure 3. Histogram showing the percent change from baseline in
joint space width (JSW) among patients defined as progressors, in the
combined North American and European studies. The narrowest JSW
in the medial compartment was measured using an automated method
of digitized radiographs and was acquired using analog techniques,
with highly standardized fluoroscopically positioned, semiflexed-view
knee radiographs at baseline and 24 months. Patients were defined as
progressors using a dichotomous definition of a 0.6 mm decrease in
JSW from baseline.
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Biochemical markers. In both the North Ameri-
can and European groups, an expected dose-dependent
decrease in the level of NTX-I with risedronate was
observed within 6 months and continued through 24
months, demonstrating effective drug delivery. The
mean percent changes from baseline to 24 months for all
doses of risedronate were statistically significantly dif-
ferent compared with placebo. In the North American
placebo group, a 7.3% increase in the level of NTX-I was
seen, with a decrease from baseline of 21.6% in patients
receiving risedronate at a dosage of 5 mg/day, a decrease
of 29.2% in those receiving risedronate at a dosage of 50
mg/week, and a decrease of 39.2% in the group receiving
risedronate at a dosage of 15 mg/day. Similarly, in the
European cohort, the level of NTX-I increased by 3.0%
in the placebo group, while decreases were seen with all
doses of risedronate (29.0% in the group receiving 5
mg/day, 28.2% in those receiving 35 mg/week, and
41.7% in those receiving 15 mg/day).
An early decrease in the level of CTX-II was seen
in risedronate-treated patients, although placebo-
treated patients had increases over the 24 months of the
study. At the highest dosage of risedronate (15 mg/day),
reductions of 17.9% and 19.6% from baseline to 24
months were seen in North American patients and
European patients, respectively, compared with in-
creases in the North American and European placebo
groups of 26.3% and 10.1%, respectively. Even greater
reductions in the levels of CTX-II (25–41%) were seen
at earlier time points in patients receiving risedronate.
Safety. Risedronate was well tolerated over 2
years, using dosages that were up to 3-fold the currently
approved dosage for osteoporosis. No clinically signifi-
cant differences in any standard laboratory parameters
(complete blood cell count, electrolytes, liver function,
renal function) were evident in the risedronate-treated
groups compared with those receiving placebo (data not
shown), and there were no differences in the number of
deaths. No significant difference was noted in the num-
ber of upper gastrointestinal (GI) adverse events be-
tween patients receiving risedronate and those receiving
placebo. There were no significant differences between
groups for prior GI disease and use of NSAIDs, aspirin,
or proton pump inhibitors (data not shown). Upper GI
adverse events were defined as abdominal pain, ulcers,
esophagitis, gastritis, dyspepsia, dysphagia, hemateme-
sis, and melena. The low rate of GI adverse events is
especially notable in patients with OA, of whom 70%
had taken an NSAID or aspirin. Furthermore, at the
highest risedronate dosage (15 mg/day or a total dose of
105 mg/week), there were fewer adverse events associ-
ated with risedronate compared with placebo, although
the difference was not statistically significant.
DISCUSSION
The Knee Osteoarthritis Structural Arthritis
(KOSTAR) trial was designed to explore the effect of
risedronate on JSN and symptoms in patients with mild
to moderate knee OA. The risedronate OA research
program consisted of 3 studies: a smaller, 285-patient
study conducted in the UK (the British Study of Risedr-
onate in Structure and Symptoms of Knee OA
[BRISK]), which focused on symptom end points (28),
and the 2 phase III studies summarized in this report,
which explored changes in JSW and symptoms as pri-
mary end points. This is the largest interventional drug
development study of knee OA reported to date, with
2,400 patients randomized, and 86.7% completing
the month 24 visit. These studies demonstrate the fea-
sibility of using centralized radiography facilities and
fluoroscopically aided radiographs for a multinational
study.
The previously reported BRISK study showed
that risedronate at a dosage of 15 mg/day improved PGA
scores over 1 year, with concomitant reductions in the
level of a marker of cartilage degradation (CTX-II) (28).
Fewer risedronate-treated patients had significant pro-
gression over 1 year compared with placebo-treated
patients. In the current multinational study, the same
techniques of measurement showed that even though
risedronate was effective for reducing bone turnover and
the level of cartilage degradation markers, no treatment
effect was demonstrated for the primary study end
points.
Signs and symptoms improved in all groups,
including placebo-treated patients, representing a
change of 20% from baseline in symptom end points,
including the total WOMAC score, WOMAC subscales,
and PGA scores. The magnitude of this improvement
has been accepted as clinically relevant at the level of the
individual patient as well as in clinical trials (39,40).
Furthermore, in patients with lower levels of pain, as
seen in this study, previously reported clinically impor-
tant improvements in both pain and PGA scores were
similar to the reductions seen in the KOSTAR trial (40).
This improvement was noted at the earliest time point
and persisted through the 2 years of the study. There
was, however, no demonstrable treatment difference in
terms of signs and symptoms for risedronate compared
with placebo. In the BRISK study, Spector et al reported
an improvement in PGA scores (28); however, the
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magnitude of the placebo-associated improvement was
not as large as that in the current study, perhaps
accounting for the significance of the treatment effect. It
is unknown whether the placebo benefit we observed
represents expectation bias on the part of patients or
whether the WOMAC index is unable to discern a
treatment effect at low background pain levels. In a
recently completed study of doxycycline (5), patients had
a similarly low level of background pain (WOMAC pain
scores of 43.2 in the index knee and 36 in the contralat-
eral knee), with no treatment effect on signs and symp-
toms in spite of an apparent treatment effect on struc-
ture in one knee but not the other. The doxycycline study
also allowed use of background analgesics, to encourage
participant retention over 30 months.
The KOSTAR trial enrolled patients who may
have been taking analgesics to control pain at baseline,
with 50% of patients in both the European and North
American groups taking NSAIDs or coxibs at baseline.
The KOSTAR study design was developed in conjunc-
tion with regulatory authorities to encourage patient
retention over 2 years, recognizing that analgesic re-
quirements are variable and may necessitate switches in
medication. Given that traditional flare-design studies of
knee OA using active comparators are associated with a
withdrawal rate of up to 30% at 6 weeks (41–43) and
even more in placebo groups, prohibiting patients from
taking rescue medication would have likely resulted in a
significant number of withdrawals over time. Other
studies of structure-modifying therapies in OA have had
dropout rates ranging from 29% to almost 50% over 2–3
years (2,7,44). Using the KOSTAR study design, an
impressive 76% of patients completed 2 years without
dropping out, and 86.7% completed the 24-month visit.
To account for differences in analgesic regimens,
at 5 days preceding study visits, patients were provided
with diclofenac and acetaminophen as the only allowable
analgesics. These agents were eliminated during the 2
days preceding visits for symptom evaluation. In spite of
analgesic washout, patients in the KOSTAR trial had
lower levels of baseline pain than have been seen in most
other studies of analgesics. Other OA studies in which
background analgesic therapy was continued have en-
rolled only patients with higher levels of background
pain, in order to demonstrate a treatment effect (45).
No treatment effect of risedronate was demon-
strated for the primary structure end points. The pro-
portions of patients in all treatment groups who demon-
strated significant progression (0.6 mm of joint space
loss) over 2 years were low (including 13% of placebo-
treated patients). Most patients showed no change over
time or changes were within the measurement error of
the technique. In the similarly designed BRISK study,
8% of placebo-treated patients demonstrated progres-
sion at 1 year, using an even more stringent definition of
progression (0.75 mm of joint space loss). In a study of
glucosamine evaluating progression of knee OA using a
fixed-extension x-ray and defining significant progres-
sion as 0.5 mm of joint space loss, only 14% of
placebo-treated patients demonstrated progression over
3 years (2).
The changes in mean JSW in all groups were also
smaller than originally anticipated. Although based on
results of prior studies (46–50) mean radiographic pro-
gression was anticipated to occur at a rate of 0.20 mm
per year, in the KOSTAR trial mean radiographic
progression was 0.088 mm over 2 years in the European
cohort and 0.13 mm in the North American cohort.
Many prior studies evaluating disease modifica-
tion in OA have shown mean changes that were less than
the measurement error of the technique of evaluation.
Using the same fluoroscopically positioned flexed-knee
view as that used in the KOSTAR trial, Brandt et al (5)
found a decrease over 30 months of 0.45 mm in the index
knee and 0.41 mm in the contralateral knee in placebo-
treated patients; this decrease is more than 3-fold
greater than that seen in the KOSTAR study. This may
be attributable to enrichment of that study with patients
with an identifiable risk factor for disease progression,
namely obesity (the mean BMI was 36.7 kg/m2, com-
pared with 30.3 kg/m2 in the North American cohort and
29.4 kg/m2 in the European cohort of the KOSTAR
study), or to the fact that patients enrolled in the
doxycycline study (5) had more cartilage at baseline.
Although the radiographic acquisition method used in
the doxycycline study was the same (with the exception
of use of digital radiographs), the analysis by Brandt et al
used a manual method of determining JSW that, al-
though reproducible, may be less accurate and reliable
than the computer-assisted measurements used in the
KOSTAR trial (34). In a study of glucosamine using
fixed extension radiographs, the mean JSW change over
3 years was 0.19 mm in the placebo group, without
enrichment for risks associated with progression (2).
Limb angulation and malalignment have been
increasingly recognized as potentially important factors
influencing the rates of radiographic progression in OA
(51). In our study, however, neither a full-length radio-
graph nor a clinical assessment of varus and valgus
alignment was performed. However, because our study
was limited to an assessment of patients in whom medial
compartment disease was greater than lateral compart-
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ment disease, we would anticipate that malalignment in
this population would be predominantly varus in nature.
Thus, some of the effects of malalignment introduced in
studies that combine medial and lateral compartment
disease may have been somewhat mitigated. The ability
to assess alignment using fluoroscopically positioned
semiflexed-view radiographs, as were obtained in this
study, is limited compared with other methods of eval-
uation (e.g., full-limb films).
Other studies have classified radiographic pro-
gression as a worsening of the Kellgren/Lawrence score,
which is dependent predominantly on osteophytes,
whereas progression in the KOSTAR trial was defined
as a significant amount of JSN. Nevertheless, no treat-
ment effect on osteophytes was observed. Although an
effect of bisphosphonates on osteophytes has been dem-
onstrated in animal models of OA (19), we did not
observe a treatment effect of risedronate. The sensitive
radiography technique used to detect changes in JSW
may not be ideal for detecting changes in osteophytes
over time, because osteophytes may not appear in
profile, thus making assessment of their size difficult. It
is also more difficult to detect changes in the categorical
grading system used for osteophyte size compared with
the linear changes derived from JSW measurement.
Many investigators have argued that a “hard”
outcome should also be used in studies of SMOADs.
Some have suggested that joint replacement represents
ultimate joint failure and could be used as such an
outcome (52). In this study, only 3% of patients
underwent joint replacement surgeries, some of which
may have been planned prior to participation in the
study, and there was no difference between treatment
groups in the numbers of nontraumatic joint replace-
ments (potentially of nonindex joints). The evaluation of
joint failure may be a possible outcome measure in
future studies but would likely require much longer
periods of followup and even larger numbers of patients.
The retention of patients in the study indicated a
high degree of compliance with the regimen. The ad-
verse events recorded did not indicate any differences
attributable to risedronate compared with placebo. The
numbers of dropouts and withdrawals were similar
across groups, and no clear relationship with the dosage
of study medication was observed. The tolerability of
dosages up to 3-fold the dosage used to treat osteo-
porosis over 2 years, especially in a population of
patients with significant concomitant background use of
NSAIDs, was impressive. In spite of concerns about
potential GI toxicity with long-term administration of
high doses, risedronate was well tolerated, with no
increase in the incidence of GI adverse events, as
previously observed (53).
Notwithstanding the lack of treatment effects on
signs and symptoms or joint space, the demonstration of
a dose-dependent reduction in a marker of cartilage
degradation (e.g., urinary CTX-II) in response to risedr-
onate was notable in both cohorts. Urinary CTX-II
levels are thought to reflect the rate of cartilage degra-
dation, and elevated levels of CTX-II have been seen in
patients with imminent progression of OA and corre-
lated with long-term progression (54,55). Similar results
were previously reported in the smaller BRISK trial
(28). Earlier studies of postmenopausal women and
patients with Paget’s disease also showed that bisphos-
phonates reduced the levels of markers of cartilage
degradation (56,57). Whether a long-term reduction in
the level of CTX-II would translate into a slower rate of
progression could not be accurately determined from
the current study, due to the limited time period.
The mechanism of action for a reduction in
CTX-II levels with risedronate is unclear. This may
represent a primary effect on subchondral bone turn-
over leading to improvement in cartilage stability. Given
that in OA subchondral bone the size and number of
trabecula are decreased (9), along with the known
benefits of bisphosphonates on improving trabecular
connectivity and bone strength (58), it is possible that
local improvement in subchondral bone strength would
better absorb load and translate into decreased levels of
biomechanical stressors on cartilage. It is unknown
whether a reduction in the level of cartilage degradation
markers would correlate with visible joint structure
changes using more sensitive imaging, but this remains
an important question for future research. Indeed, re-
ductions in the level of CTX-II have been recently
reported to track with MR images of subchondral le-
sions in OA knees over 3 months (59).
This study demonstrates the challenges associ-
ated with evaluating a medication that may affect signs
and symptoms along with a radiographic outcome and in
developing a study design that will evaluate both out-
comes. Although controlling pain is important for pa-
tient retention in a study, the measures used to control
this pain may result in a high placebo response, as
demonstrated here. Conversely, although patients with
mild pain are potentially appropriate for enrollment in a
longer-term study of structure modification, such pa-
tients may not be appropriate for studying an effect on
signs and symptoms. Plain radiography, even over 2
years, will detect only a small number of progressors, as
defined by stringent criteria that take into account the
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measurement error of the radiographic technique. As is
also the case in RA clinical studies, a small number of
patients drive mean changes, with most patients experi-
encing no change during the course of the study. Defin-
ing clinical, biochemical, and genetic predictors of pro-
gression is important. Further analyses such as these
may indicate a more appropriate group to study for
future clinical trials (60,61). Although MRI may be more
sensitive in detecting structural changes over time
(59,62), additional correlation with plain radiography is
still likely to be required by drug regulatory agencies and
by the rheumatology community.
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